The impact of the prevalence of glutathione S-transferase polymorphism on the response of Egyptian CML patients to tyrosine kinase inhibitor (imatinib) / (Record no. 172009)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 05293namaa22004331i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OSt |
| 005 - أخر تعامل مع التسجيلة | |
| control field | 20250522113200.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 250511s2024 ua a|||fr|m|| 000 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloguing agency | EG-GICUC |
| Language of cataloging | eng |
| Transcribing agency | EG-GICUC |
| Modifying agency | EG-GICUC |
| Description conventions | rda |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| Language code of summary or abstract | eng |
| -- | ara |
| 049 ## - Acquisition Source | |
| Acquisition Source | Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.99419 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) | |
| Classification number | 616.99419 |
| Edition number | 21 |
| 097 ## - Degree | |
| Degree | Ph.D |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| Local Call Number | Cai01.11.18.Ph.D.2024.Am.I. |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Authority record control number or standard number | Amr Mohammed Abd El Fattah, |
| Preparation | preparation. |
| 245 14 - TITLE STATEMENT | |
| Title | The impact of the prevalence of glutathione S-transferase polymorphism on the response of Egyptian CML patients to tyrosine kinase inhibitor (imatinib) / |
| Statement of responsibility, etc. | By Amr Mohammed Abd El Fattah; Under Supervision of Prof. Dr. Nehad Mohammed Tawfeek, Dr. Mohamed Ahmed Fateen, Dr. Ibrahim Ahmed Ibrahim Abdalgawad / |
| 246 15 - VARYING FORM OF TITLE | |
| Title proper/short title | تأثير انتشار الجلوتاثيون S- ترانسفيراز تعدد الأشكال علي الإستجابة من المرضي المصريين المصابين بسرطان الدم النخاعى المزمن الى الخط الأول من مثبطات التيروزين كيناز(ايماتينيب) / |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 2024. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 84 pages : |
| Other physical details | illustrations ; |
| Dimensions | 25 cm. + |
| Accompanying material | CD. |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Source | rda content |
| 337 ## - MEDIA TYPE | |
| Media type term | Unmediated |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | volume |
| Source | rdacarrier |
| 502 ## - DISSERTATION NOTE | |
| Dissertation note | Thesis (Ph.D)-Cairo University, 2024. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Bibliography: pages 79-84. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Rationale: Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm <br/>with an incidence of 1-2 cases per 100 000 adults. It accounts for approximately <br/>15% of newly diagnosed cases of leukemia in adults. Tyrosine kinase inhibitors <br/>(TKIs) had significantly changed the treatment landscape, improving outcomes <br/>for patients with CML treatment. First generation TKIs imatinib had improved <br/>the 8-years overall survival rate from 20 to 87%. Four generations of TKIs were <br/>approved and commonly used for the treatment of CML. The occurrence of <br/>CML is controlled by a set of factors such as exposure to environmental <br/>carcinogens and the ability to eliminate toxic substances. Resistance to tyrosine <br/>kinase inhibitors constitutes a big challenge in the treatment of patients with <br/>CML. This resistance could be linked to glutathione transferase activity. <br/>Several studies in literature studied the impact of glutathione over CML patients <br/>as risk of both susceptibility, treatment resistance and poor response. <br/>Purpose: This study aims to evaluate the presence of Glutathione transferase <br/>polymorphism on CML patients and the impact of glutathione s polymorphism <br/>on the molecular response BCR-ABL (IS %) on CML patients on the first line <br/>tyrosine kinase inhibitor (imatinib) <br/>Methodology: The study included 50 patients with chronic myeloid leukemia <br/>receiving tyrosine kinase inhibitor imatinib were recruited from outpatient <br/>hematology clinic at kasr El Einy hospital and followed over the period from <br/>October 2021 to October 2023. The patients were investigated for routine <br/>laboratory investigations including complete blood picture, liver functions, <br/>renal functions, molecular BCR-ABL (IS %) and glutathione s polymorphism <br/>Results: The study results show correlation between molecular response BCR-<br/>ABL (IS %) of different groups of the study and severity of anemic <br/>manifestations with statistically significant difference of p value 0.023. The <br/>results of the study show no correlation between Glutathione S polymorphism <br/>and molecular response of CML cases among study group as no statistically <br/>significance difference with p value 0.94 so the study shows no impact of the <br/>GSP1 on the molecular response of the patients |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | تهدف دراستنا إلى تقييم انتشار و تأثير تعدد أشكال الجلوتاثيون على الاستجابة الجزيئية لدى المرضى المصريين بسرطان الدم الميلودي المزمن للجيل لأول من مثبطات التيروزين كيناز (ايماتينيب).<br/>وجدت الدراسة وجود علاقة ذات دلالة إحصائية بين الاستجابة الجزيئية و حدة أعراض فقر الدم بين المجموعات المختلفة حيث وجدنا تحسن في أعراض فقر الدم مع تحسن الاستجابة الجزيئية مع عدم وجود تأثير لتعدد أشكال الجلوتاثيون S على الاستجابة الجزيئية في حالات سرطان الدم النخاعي المزمن على إيماتينيب |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE | |
| Issues CD | Issued also as CD |
| 546 ## - LANGUAGE NOTE | |
| Text Language | Text in English and abstract in Arabic & English. |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Leukemia |
| Source of heading or term | qrmak |
| 653 #0 - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | CML (Chronic myeloid leukemia) |
| -- | Imatinib resistance |
| -- | TKIs (Tyrosine kinase inhibitor ) |
| -- | GSTs (Glutathione transferases) |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Nehad Mohammed Tawfeek |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mohamed Ahmed Fateen |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ibrahim Ahmed Ibrahim Abdalgawad |
| Relator term | thesis advisor. |
| 900 ## - Thesis Information | |
| Grant date | 01-01-2024 |
| Supervisory body | Nehad Mohammed Tawfeek |
| -- | Mohamed Ahmed Fateen |
| -- | Ibrahim Ahmed Ibrahim Abdalgawad |
| Universities | Cairo University |
| Faculties | Faculty of Medicine |
| Department | Department of Internal Medicine |
| 905 ## - Cataloger and Reviser Names | |
| Cataloger Name | Nourhan |
| Reviser Names | Eman Ghareb |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Thesis |
| Edition | 21 |
| Suppress in OPAC | No |
| Source of classification or shelving scheme | Home library | Current library | Date acquired | Inventory number | Full call number | Barcode | Date last seen | Effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | المكتبة المركزبة الجديدة - جامعة القاهرة | قاعة الرسائل الجامعية - الدور الاول | 11.05.2025 | 91105 | Cai01.11.18.Ph.D.2024.Am.I. | 01010110091105000 | 11.05.2025 | 11.05.2025 | Thesis |